Initial Evaluation of Photorefractive Keratectomy in U.S. Army Personnel

NCT ID: NCT00413673

Last Updated: 2008-04-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-08-31

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to conduct a prospective clinical trial to evaluate the safety and efficacy fo the VISX Excimer Laser system for the treatment of naturally occurring low to moderate myopia, with or without low levels of astigmatism, in U.S. Army personnel.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Naturally occurring low to moderate myopia, with or without low levels of astigmatism in U.S. Army personnel

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

PRK

Group Type EXPERIMENTAL

PRK

Intervention Type PROCEDURE

PRK

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRK

PRK

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent.
* Normal, healthy active adults with access to medical care at Walter Reed Health Care System.
* Age 21 years or older.
* Spherical equivalent of the manifest refractive error between -1.0 to -6.0 diopters (D), inclusive, with no more than 3.0D of cylinder. The absolute value of the cylinder (expressed in minus cylinder) will be limited such that the short axis of the elliptical ablation will be no smaller than 4.9mm. The following specifies the maximum cylinder for a given spherical component of the manifest refraction:

Spherical component / Maximum cylinder

* 1.0D / -0.5D
* 2.0D / -1.0D
* 3.0D / -1.5D
* 4.0D / -2.0D
* 5.0D / -2.5D
* 6.0D / -3.0D
* Corrected vision of at least 20/20
* Soft contact lens users must havE removed their lenses at least two weeks prior to baseline measurements.
* Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least four weeks prior to baseline measurements. At least two weekly manifest refractions and keratometry measurements will be required in this interval. The last two measurements must not vary by more than 0.50D in any meridian.
* Patients undergoing orthokeratology must have their lenses removed at least 6 months prior to the baseline examination. At least two monthly manifest refractions and keratometry measurements taken after the third month out of lenses must not vary by more than 0.50D in any meridian.
* Refractive stability must be documented by previous refractions. Spherical and cylindrical portion of the manifest refraction must not have varied by more than 0.50D over the previous 12 months.
* Exhibits strong motivation for keeping the follow-up visits.
* Available for evaluation at Walter Reed during the two-year follow-up period.
* Service members must have their command approval to participate in the study.
* Access to transportation to meet follow-up requirements.

Exclusion Criteria

* Residual, recurrent or active ocular diseases or corneal abnormalities in either eye such as iritis, uveitis, keratoconjunctivitis sicca, herpetic keratitis, vernal conjunctivitis, lagophthalmos, corneal scarring, glaucoma, previous steroid responder, occludable chamber angles, visually significant cataracts.
* Either one or both eyes suffering from chronic dryness.
* Taking any systemic medications that may affect wound healing such as corticosteroids or antimetabolites.
* Patient corneal neovascularization within one mm of the ablation zone.
* History of any previous eye surgery, including previous refractive surgery.
* Best corrected visual acuity of less than 20/20.
* Progressive myopia or keratoconus.
* Any systemic disease that may affect wound healing, such as connective tissue disorders (rheumatoid arthritis, systemic lupus erythematosus, etc.), diabetes, or severe atopic disease.
* Any physical or mental impairment that would preclude participation in any of the examinations.
* For contact lens users there must be no evidence of contact lens corneal warpage on computerized topography.
* Currently on flight status or projected to be on flight status within ten years.
* Pregnant or breast-feeding an infant. Women of childbearing age must take a urine blood pregnancy test before starting this study
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Walter Reed Army Medical Center

FED

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

KRAIG S. BOWER, MD

Role: PRINCIPAL_INVESTIGATOR

Walter Reed Army Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Walter Reed Army Medical Center, Center For Refractive Surgery

Washington D.C., District of Columbia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

WRAMC WU # 2335-99

Identifier Type: -

Identifier Source: org_study_id